# A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

> **NCT07489599** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 68 (estimated)

## Conditions studied

- Alzheimer's Disease(AD)
- Mild Cognitive Impairment (MCI)

## Interventions

- **DRUG:** QLH2405
- **DRUG:** QLH2405
- **DRUG:** Placebo
- **DRUG:** QLH2405
- **DRUG:** Placebo
- **DRUG:** QLH2405
- **DRUG:** Placebo
- **DRUG:** QLH2405
- **DRUG:** Placebo
- **DRUG:** QLH2405
- **DRUG:** Placebo
- **DRUG:** QLH2405
- **DRUG:** Placebo
- **DRUG:** QLH2405
- **DRUG:** Placebo
- **DRUG:** QLH2405
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07489599
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489599, "A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07489599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*